• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    PTC Therapeutics, Inc. - Common Stock (NQ:PTCT)

    66.82 UNCHANGED
    Streaming Delayed Price Updated: 4:15 PM EDT, Oct 16, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 2,478
    Open 66.82
    Bid (Size) 48.31 (1)
    Ask (Size) 70.70 (1)
    Prev. Close 66.82
    Today's Range 66.82 - 66.82
    52wk Range 35.51 - 69.48
    Shares Outstanding 79,378,145
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    PTC THERAPEUTICS INC (NASDAQ:PTCT) Presents a Compelling Case for Affordable Growth Investing
    PTC Therapeutics (PTCT) offers strong growth with a 96% revenue surge, yet trades at a reasonable P/E of 10.94, making it a compelling GARP investment. 
    Via Chartmill
    PTC THERAPEUTICS INC (NASDAQ:PTCT) Combines Strong Growth with Bullish Technical Setup
    PTC Therapeutics (PTCT) combines explosive sales growth and strong earnings with an attractive valuation and bullish technical setup for a compelling investment profile. 
    Via Chartmill

    Performance

    YTD
    +45.6%
    +45.6%
    1 Month
    +11.9%
    +11.9%
    3 Month
    +37.7%
    +37.7%
    6 Month
    +41.0%
    +41.0%
    1 Year
    +82.1%
    +82.1%

    More News

    Read More
    PTC THERAPEUTICS INC (NASDAQ:PTCT): An Affordable Growth Candidate in Biotech
    Via Chartmill
    PTC Therapeutics Could Challenge BioMarin For Metabolic Disorder Treatment
    Via Benzinga
    Here's Why Shares in PTC Therapeutics Soared This Week
    Via The Motley Fool
    Earnings Scheduled For August 7, 2025
    Via Benzinga
    PTC Therapeutics Earnings Preview
    Via Benzinga
    PTC Therapeutics Stock Is Stuck In A Multi-Year Slump
    Via Benzinga
    PTC THERAPEUTICS INC (NASDAQ:PTCT) Emerges as a Top Affordable Growth Stock
    Via Chartmill
    PTC Therapeutics Stock In The Spotlight After FDA Refuses Approval For Drug To Treat Neurodegenerative Disease, Analysts Are Divided
    Via Stocktwits
    PTC Therapeutics Faces FDA Rejection On Rare Disease Treatment Over Efficacy Concerns
    Via Benzinga
    PTCT Earnings Beat but Sales Drop 4%
    Via The Motley Fool
    Topics Earnings
    PTC THERAPEUTICS INC (NASDAQ:PTCT) Reports Q2 2025 Earnings Beat with Narrowed Loss and Strong Sephience™ Launch
    Via Chartmill
    Topics Earnings
    Sephience Gets FDA Approval, Now A Key Revenue Driver For PTC Therapeutics
    Via Benzinga
    These Analysts Increase Their Forecasts On PTC Therapeutics
    Via Benzinga
    FDA Approval Sparks Bullish Momentum In PTC Therapeutics — Here’s What Happened
    Via Stocktwits
    12 Health Care Stocks Moving In Monday's After-Market Session
    Via Benzinga
    PTC THERAPEUTICS INC (NASDAQ:PTCT) – A Strong Growth Stock at a Fair Valuation
    Via Chartmill
    PTC THERAPEUTICS INC (NASDAQ:PTCT) - A Biotech Stock With Strong Growth and Reasonable Valuation
    Via Chartmill
    PTC THERAPEUTICS INC (NASDAQ:PTCT) – A Strong Growth Stock with Technical Breakout Potential
    Via Chartmill
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
    Via ACCESS Newswire
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
    From Pomerantz LLP
    Via GlobeNewswire
    PTCT Investors Have Opportunity to Join PTC Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
    From The Schall Law Firm
    Via Business Wire
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
    From Pomerantz LLP
    Via GlobeNewswire
    PTC THERAPEUTICS INC (NASDAQ:PTCT) - A Biotech Stock With Strong Growth and Reasonable Valuation
    Via Chartmill

    Frequently Asked Questions

    Is PTC Therapeutics, Inc. - Common Stock publicly traded?
    Yes, PTC Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does PTC Therapeutics, Inc. - Common Stock trade on?
    PTC Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for PTC Therapeutics, Inc. - Common Stock?
    The ticker symbol for PTC Therapeutics, Inc. - Common Stock is PTCT on the Nasdaq Stock Market
    What is the current price of PTC Therapeutics, Inc. - Common Stock?
    The current price of PTC Therapeutics, Inc. - Common Stock is 66.82
    When was PTC Therapeutics, Inc. - Common Stock last traded?
    The last trade of PTC Therapeutics, Inc. - Common Stock was at 10/16/25 04:15 PM ET
    What is the market capitalization of PTC Therapeutics, Inc. - Common Stock?
    The market capitalization of PTC Therapeutics, Inc. - Common Stock is 5.30B
    How many shares of PTC Therapeutics, Inc. - Common Stock are outstanding?
    PTC Therapeutics, Inc. - Common Stock has 5B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.